Impact of Factor V Leiden Polymorphism in Patients with PCOS

1. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev. 2016;37(5):467-520. doi:10.1210/er.2015-1104.10.1210/er.2015-1104Open DOISearch in Google Scholar

2. Melo AS, Dias SV, Cavalli RC, Cardoso VC, Bettiol H, Barbieri MA, et al. Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause. Reproduction. 2015;150(1):R11-24.10.1530/REP-14-0499Search in Google Scholar

3. Zueff LFN, Martins WP, Vieira CS, Ferriani RA. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol. 2012;39(3):341-7.10.1002/uog.10084Search in Google Scholar

4. Sir-Petermann T, Angel B, Maliqueo M, Carvajal F, Santos JL, Perez-Bravo F. Prevalence of type II diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia. 2002;45:959-64.10.1007/s00125-002-0836-3Search in Google Scholar

5. Kiddy DS, Sharp PS, White DM, Scanlon MF, Mason HD, Bray CS, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol (Oxf). 1990;32(2):213-20.10.1111/j.1365-2265.1990.tb00857.xSearch in Google Scholar

6. Legro RS, Strauss JF. Molecular progress in infertility: polycystic ovary syndrome”. Fertility and Sterility. 2002;78 (3):569-76.10.1016/S0015-0282(02)03275-2Search in Google Scholar

7. Crosignani PG, Nicolosi AE. Polycystic ovarian disease: heritability and heterogeneity. Hum Reprod. 2001;7(1):3-7.10.1093/humupd/7.1.3Search in Google Scholar

8. Sampson M, Kong C, Patel A, Unwin R & Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol. 1996;45(5):623-9.10.1046/j.1365-2265.1996.00863.xSearch in Google Scholar

9. Lee YH, Song GG. Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2014;175:8-14.10.1016/j.ejogrb.2013.12.030Search in Google Scholar

10. Orio F Jr, Palomba S, Cascella T, Tauchmanova L, Nardo LG, Labella D, et al. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod Biomed Online. 2004;9(5):505-10.10.1016/S1472-6483(10)61634-3Search in Google Scholar

11. Glueck CJ, Wanga P, Bornovali S, Goldenberg N, Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism. 2003;52(12):1627-32.10.1016/j.metabol.2003.06.00114669168Search in Google Scholar

12. Tsanadis G, Vartholomatos G, Korkontzelos I, Avgoustatos F, Kakosimos G, Sotiriadis A, et al. Polycystic ovarian syndrome and thrombophilia. Hum Reprod. 2002;17(2):314-9.10.1093/humrep/17.2.31411821270Search in Google Scholar

13. T. Kazerooni, F. Ghaffarpasand, N. Asadi, Z. Dehkhoda,M. Dehghankhalili, Y. Kazerooni. Correlation between thrombophilia and recurrent pregnancy loss in patients with polycystic ovary syndrome: A comparative study. J Chin Med Assoc. 2013;76(5):282-8.10.1016/j.jcma.2013.01.00923683262Search in Google Scholar

14. Moini A, Tadayon S, Tehranian A, Yeganeh LM, Akhoond MR, Yazdi RS. Association of thrombophilia and polycystic ovarian syndrome in women with history of recurrent pregnancy loss. Gynecol Endocrinol. 2012;28(8):590-593.10.3109/09513590.2011.65075422452370Search in Google Scholar

15. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-7.10.1093/humrep/deh09814688154Search in Google Scholar

16. Komsa-Penkova R, Kovacheva-Kotseva K, Angelova S, Savov A, Semionova M. [Selected methods of DNA analysis and clinical applications]. Pleven: Medical University - Pleven; 2004. BulgarianSearch in Google Scholar

17. Lash GE, Naruse K, Innes BA, Robson SC, Searle RF, Bulmer JN. Secretion of angiogenic growth factors by villous cytotrophoblast and extravillous trophoblast in early human pregnancy. Placenta. 2010;31(6):545-8.10.1016/j.placenta.2010.02.02020338637Search in Google Scholar

18. Schatz F, Guzeloglu-Kayisli O, Arlier S1, Kayisli UA, Lockwood CJ. The role of decidual cells in uterine hemostasis, menstruation, inflammation, adverse pregnancy outcomes and abnormal uterine bleeding. Hum Reprod . 2016;22(4):497-515.10.1093/humupd/dmw004491774226912000Search in Google Scholar

19. Ivanov P, Komsa-Penkova R, Kovacheva K, Konova E, Simeonova M. Influence of factor V LEIDEN carrier on the development of reproductive disorders in different periods of pregnancy. Medical review. 2008;1:68-71.Search in Google Scholar

20. Ivanov P, Konova E, Gecheva S, Cviatkovska C, Izmajlov A, Komsa-Penkova R. et al. Factor V Leiden in assisted reproductive technology. Obstetrics and Gynecology.2013; 6:11-14.Search in Google Scholar

21. Atiomo WU, Condon J, Adekanmi O, Friend J, Wilkin TJ, Prentice AG. Are women with polycystic ovary syndrome resistant to activated protein C? Fertil Steril. 2000;74:1229-1232.10.1016/S0015-0282(00)01614-9Search in Google Scholar